Results 31 to 40 of about 3,233,582 (249)
Recent Innovations in Lipid-lowering Therapies
Guoji laonian yixue zazhiDyslipidemia is a major risk factor for atherosclerotic cardiovascular diseases. Recent advancements in lipid-lowering therapies have seen progress with statins, cholesterol absorption inhibitors, PCSK9 inhibitors, and omega-3 fatty acids becoming widely
Xin Hu, Xiaoming Wang
doaj +1 more source
Lipid Lowering Therapy According to Clinical Outcomes in Elderly Population
, 2022 A systematic review of statin therapy and other lipid lowering agents and their efficacies in regard to the elderly population. In this review, I have introduced lipid metabolism and storage in the body.
Issa, Rabeh
core
Lipid-lowering therapy in the outpatient practice
Медицинский совет, 2013 The review focuses on the importance of primary and secondary prevention of cardiovascular disease in outpatient settings, and principles of effective and safe use of modern lipid-lowering drugs.
S. A. Urazgildeyeva
doaj +1 more source
Lipids in Health and Disease, 2021 Background Large observational studies have shown that small, dense LDL subfractions are related to atherosclerotic cardiovascular disease. This study assessed the effects of two highly effective lipid-lowering therapies in the atherogenic subclasses of ...
Leticia C. S. Pinto +11 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2023 Dyslipidemia is one of the most significant modifiable cardiovascular risk factors. The change in the modern paradigm for dyslipidemia treatment from high-intensity statin therapy to high-intensity lipid-lowering therapy makes it possible to more often ...
A. B. Skiba +5 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019 Background The relationship between lowering LDL (low‐density lipoprotein) cholesterol with contemporary lipid‐lowering therapies and incident diabetes mellitus (DM) remains uncertain.
Safi U. Khan +9 more
doaj +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
FEBS Letters, EarlyView.Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
Optimal lipid modification: the rationale for combination therapy [PDF]
, 2005 James M Backes1, Cheryl A Gibson2, Patricia A Howard31Department of Pharmacy Practice, Lipid, Atherosclerosis, Metabolic and LDL Apheresis Center, University of Kansas Medical Center, Kansas City, KS, USA; 2Department of Internal Medicine, University of ...
James M Backes +5 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Prevalence and types of persistent dyslipidemia in patients treated with statins [PDF]
, 2013 Aim To determine the prevalence and types of persistent dyslipidemia in patients treated with different statins to reduce cardiovascular disease (CVD) risk, as well as to determine the proportion of high risk patients who did not reach the lipid ...
Željko Reiner +3 more
core +1 more source